Severe rituximab-induced pneumonitis in an immunocompromised child with acquired thrombotic thrombocytopenic purpura

Pediatr Blood Cancer. 2022 Feb;69(2):e29375. doi: 10.1002/pbc.29375. Epub 2021 Oct 6.

Authors

Anna Maria Testi¹, Maria Luisa Moleti¹, Paola Papoff², Francesca Paoletti¹, Silvia Trisolini¹, Maria Stefania De Propris¹, Simona Bianchi¹, Francesca Kaiser¹, Giuseppe Gentile¹

Affiliations

¹ Department of Translational and Precision Medicine, Sapienza University of Rome, Rome.
² Department of Pediatrics, Pediatric Intensive Care Unit, Umberto I Policlinico, Sapienza University of Rome, Rome, Italy.

PMID: 34613663
DOI: 10.1002/pbc.29375

No abstract available

Keywords: Thrombotic thrombocytopenic purpura; pediatric age; pneumonitis; rituximab.

Publication types

Letter

MeSH terms

ADAMTS13 Protein
Child
Humans
Pneumonia*
Purpura, Thrombotic Thrombocytopenic* / chemically induced
Rituximab / adverse effects

Substances

Rituximab
ADAMTS13 Protein

Supplementary concepts

Thrombotic thrombocytopenic purpura, acquired